Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E−/−mice

What is it about?

This study for the first time show that Aspirin-triggered lipoxin A4 (ATL) can stop the progression of experimental atherosclerosis, and provides arguments for a therapeutic benefit of this lipid mediator in cardiovascular disease by means of stimulating the resolution of inflammation.

Featured Image